» Articles » PMID: 34889416

Indications for Transfusion in the Management of Sickle Cell Disease

Overview
Specialty Hematology
Date 2021 Dec 10
PMID 34889416
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The transfusion of red blood cells (RBCs) is a crucial treatment for sickle cell disease (SCD). While often beneficial, the frequent use of transfusions is associated with numerous complications. Transfusions should be offered with specific guidelines in mind. Here we present updates to the indications for transfusion of RBCs in SCD. We review recent publications and include expert perspectives from hematology and transfusion medicine. For some clinical indications, such as ischemic stroke, the role of transfusion has been well studied and can be applied almost universally. For many other clinical scenarios, the use of transfusion therapy has less conclusive data and therefore must be tailored to individual needs. We highlight the roles of RBC transfusions in preventing or mitigating neurological disease, in reducing perioperative complications, in managing acute chest syndrome, and in optimizing pregnancy outcomes in SCD. We further highlight various transfusion techniques and when each might be considered. Potential complications of transfusion are also briefly discussed.

Citing Articles

Quality of Life and Out-of-Pocket Expenditures for Sickle Cell Disease Patients in Saudi Arabia: A Single-Center Study.

AlRuthia Y, Alanazi R, Alotaibi S, Alanazi M Healthcare (Basel). 2024; 12(21).

PMID: 39517358 PMC: 11545741. DOI: 10.3390/healthcare12212146.


Therapeutics for sickle cell disease intravascular hemolysis.

Xue J, Li X Front Physiol. 2024; 15:1474569.

PMID: 39345787 PMC: 11427376. DOI: 10.3389/fphys.2024.1474569.


Prevalence and predictors of iron deficiency anaemia among children with sickle cell disease in Dodoma, Tanzania: a cross-sectional study.

Bossy A, Yahaya J, Jumanne S BMC Public Health. 2024; 24(1):1026.

PMID: 38609881 PMC: 11015568. DOI: 10.1186/s12889-024-18438-5.


First investigation of RH gene polymorphism in patients with sickle cell disease and associated blood donors in Cameroon, Central Africa.

Mbeti J, Benech C, Sack F, Wete E, Pangetha H, Ateba S Blood Transfus. 2024; 22(5):377-386.

PMID: 38315540 PMC: 11390615. DOI: 10.2450/BloodTransfus.660.


Robotic-assisted versus laparoscopic splenectomy in children: a costeffectiveness study.

Delgado-Miguel C, Camps J J Robot Surg. 2024; 18(1):51.

PMID: 38280120 DOI: 10.1007/s11701-023-01783-9.


References
1.
El-Gohary Y, Fleming A, Zhang H, Estepp J, Hankins J, Wang W . Acute Chest Syndrome After Splenectomy in Children With Sickle Cell Disease. J Surg Res. 2019; 242:336-341. DOI: 10.1016/j.jss.2019.04.077. View

2.
Galadanci N, Abdullahi S, Ali Abubakar S, Jibir B, Aminu H, Tijjani A . Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. Am J Hematol. 2020; 95(9):E247-E250. PMC: 8697367. DOI: 10.1002/ajh.25900. View

3.
Fort R . Recommendations for the use of red blood cell exchange in sickle cell disease. Transfus Apher Sci. 2019; 58(2):128-131. DOI: 10.1016/j.transci.2019.03.004. View

4.
Yazdanbakhsh K . Mechanisms of sickle cell alloimmunization. Transfus Clin Biol. 2015; 22(3):178-81. PMC: 4806679. DOI: 10.1016/j.tracli.2015.05.005. View

5.
Unnikrishnan A, Pelletier J, Bari S, Zumberg M, Shahmohamadi A, Spiess B . Anti-N and anti-Do immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Transfusion. 2019; 59(6):1907-1910. DOI: 10.1111/trf.15198. View